Madrigal Q2 FY26 net loss widens to $57.9 million; net sales rise 71% to $364.3 million - MDGL News | RalliesMadrigal Q2 FY26 net loss widens to $57.9 million; net sales rise 71% to $364.3 million
M
MDGL• Q2 results and cash position
- Madrigal posted 2Q 2026 net sales of $364.3 million, up 71% year over year.
- Net loss widened to $57.9 million; loss per share widened to $1.99.
- Operating expenses climbed to $420.6 million, including cost of sales of $40 million.
- Cash, cash equivalents, restricted cash and marketable securities fell to $838.9 million as of June 30, 2026.
- Patient count topped 49,000 as of June 30, 2026; Phase 1 dosing began for oral GLP-1 candidate MGL-2086 in June.
•
